Inhibition of protein kinase C but not protein kinase A attenuates morphine withdrawal excitation of rat hypothalamus-pituitary-adrenal axis

European Journal of Pharmacology

Volumn 452, Issue 1, 2002, Pages 57-66

  Cerezo, Manuela ^a   Laorden, M Luisa ^a   Milanes M Victoria ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Corticosterone; Dopamine turnover; Hypothalamus pituitary adrenocortical axis; Morphine withdrawal; Noradrenaline turnover; PKA (protein kinase A); PKC (protein kinase C)

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; CALPHOSTIN C; CORTICOSTERONE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; DOPAMINE; MORPHINE; N (2 GUANIDINOETHYL) 5 ISOQUINOLINESULFONAMIDE; NALOXONE; NORADRENALIN; PROTEIN KINASE C INHIBITOR;

ADRENAL CORTEX; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CATECHOLAMINERGIC SYSTEM; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOSTERONE RELEASE; DRUG WITHDRAWAL; ENZYME INHIBITION; HYPOPHYSIS ADRENAL SYSTEM; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; THALAMUS MIDLINE NUCLEUS;

3,4-DIHYDROXYPHENYLACETIC ACID; ANALGESICS, OPIOID; ANIMALS; BLOOD-BRAIN BARRIER; CATECHOLAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORTICOSTERONE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME INHIBITORS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; ISOQUINOLINES; MALE; METHOXYHYDROXYPHENYLGLYCOL; MORPHINE; NAPHTHALENES; NOREPINEPHRINE; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PITUITARY-ADRENAL SYSTEM; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE WITHDRAWAL SYNDROME; SULFONAMIDES;

EID: 0037183752     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02245-8     Document Type: Article

References (40)

1. Artigas F., Sarrias M.J., Adell A., Gelpí E. Quantitation of total MHPG in the rat brain using a non enzymatic hydrolysis procedure. Effects of drugs. Life Sci. 39:1986;1571-1578.
2. Chen C.L., Chen H., Zhu D.M., Uckun F.M. Quantitative high-performance liquid chromatography-based detection method for calphostin C, a naturally occurring perylenequinone with potent antileukemic activity. J. Chromatogr. B. 724:1999;157-162.
3. Chen C.L., Tai H.L., Zhu D.M., Uckun F.M. Pharmacokinetic features and metabolism of calphostin C, a naturally occurring perylenequinone with antileukemic activity. Pharm. Res. 16:1999;1003-1009.
4. Childers S.R. Opioid receptor-coupled second messengers systems. Life Sci. 48:1991;1991-2003.
5. Couceyro P., Douglass J. Precipitated morphine withdrawal stimulates multiple activator protein-1 signaling pathways in rat brain. Mol. Pharmacol. 47:1995;29-39.
6. Cunningham E.T., Sawchenko P.E. Anatomical specificity of noradrenergic inputs to the paraventricular and supraoptic nuclei of the rat hypothalamus. J. Comp. Neurol. 274:1988;60-76.
7. Eaton M.J., Cheung S., Moore K.E., Lookingland K.J. Dopamine receptor-mediated regulation of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res. 738:1996;60-66.
8. Fuertes G., Laorden M.L., Milanés M.V. Noradrenergic and dopaminergic activity in the hypothalamic paraventricular nucleus after naloxone-induced morphine withdrawal. Neuroendocrinology. 71:2000;60-67.
9. Fuertes G., Milanés M.V., Rodríguez-Gago M., Marín M.T., Laorden M.L. Changes in hypothalamic paraventricular nucleus catecholaminergic activity after acute and chronic morphine administration. Eur. J. Pharmacol. 388:2000;49-56.
10. Gonzálvez M.L., Milanés M.V., Martínez-Piñero M.G., Marín M.T., Vargas M.L. Effects of intracerebroventricular clonidine on the hypothalamic noradrenaline and plasma corticosterone levels of opiate naïve rats and after naloxone-induced withdrawal. Brain Res. 647:1994;199-203.
11. Guitart X., Nestler E.J. Identification of morphine- and cyclic AMP-regulated phosphoprotein (MARPPs) in the locus coeruleus and other regions of rat brain: regulation by acute and chronic morphine. J. Neurosci. 9:1989;4371-4387.
12. Hidaka H., Imagaki M., Kawamoto S., Sasaki V. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry. 23:1984;5036-5041.
13. Ignar D.M., Kuhn C.M. Effects of specific Mu and Kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat. J. Pharmacol. Exp. Ther. 255:1990;1287-1295.
14. Itoi K., Suda T., Tozawa F., Dobashi I., Ohmori N., Sakai Y., Abe K., Demura H. Microinjection of norepinephrine into the paraventricular nucleus of the hypothalamus stimulates corticotropin-releasing factor gene expression in conscious rats. Endocrinology. 135:1994;2177-2182.
15. Itoi K., Horiba N., Tozawa F., Sakai Y., Sakai K., Demura H., Suda T. Major role of 3′,5′-cyclic adenosine monophosphate-dependent protein kinase A pathways in corticotropin-releasing factor gene expression in the rat hypothalamus in vivo. Endocrinology. 137:1996;2389-2396.
16. Itoi K., Seasholtz A.F., Watson S.J. Cellular and extracellular regulatory mechanisms of hypothalamic corticotropin-releasing hormone neurons. Endocr. J. 45:1998;13-33.
17. Itoi K., Helmreich D.L., Lopez-Figueroa M., Watson S.J. Differential regulation of corticotropin-releasing hormone and vasopressin gene transcription in the hypothalamus by norepinephrine. J. Neurosci. 19:1999;5464-5472.
18. Kobayashi E., Nakano H., Morimoto M., Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 159:1989;548-553.
19. 2-adrenoceptors. J. Pharmacol. Exp. Ther. 293:2000;578-584.
20. Laorden M.L., Castells M.T., Milanés M.V. Effects of morphine and morphine withdrawal on brainstem neurons innervating hypothalamic nuclei that control the pituitary-adrenocortical axis in rats. Br. J. Pharmacol. 136:2002;67-75.
21. Lookingland K.J., Ireland L.M., Gunnet J.W., Manzanares J., Tian Y., Moore K.E. 3-Methoxy-4-hydroxyphenylethyleneglycol concentrations in discrete hypothalamic nuclei reflect the activity of noradrenergic neurons. Brain Res. 559:1991;82-88.
22. Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci. Biobehav. Rev. 1:1997;91-104.
23. Mao J., Price D.D., Mayer D.J. Increases in protein kinase C gamma immunoreactivity in the spinal cord of rats associated with tolerance to the analgesic effects of morphine. Brain Res. 677:1995;257-267.
24. Martínez-Piñero M.G., Milanés M.V., Alcaraz C., Vargas M.L. Catecholaminergic mediation of morphine-induced activation of pituitary-adrenocortical axis in the rat: implication of α- and β-adrenoceptors. Brain Res. 668:1994;122-128.
25. Milanés M.V., Laorden M.L., Chapleur-Chateau M., Burlet A. Alterations in corticotropin-releasing factor and vasopressin content in rat brain during morphine withdrawal. Correlation with hypothalamic noradrenergic activity and pituitary-adrenal response. J. Pharmacol. Exp. Ther. 285:1998;700-706.
26. Narita M., Makimura M., Feng Y., Hoskins B., Ho I.K. Influence of chronic morphine treatment on protein kinase C activity: comparison with butorphanol and implication for opioid tolerance. Brain Res. 650:1994;175-179.
27. Nestler E.J. Molecular mechanism of drug addiction. J. Neurosci. 12:1992;2439-2450.
28. Nestler E.J., Aghajanian G.K. Molecular and cellular basis of addiction. Science. 278:1997;58-63.
29. Palkovits M. Isolated removal of hypothalamic or other brain nuclei of the rat. Brain Res. 59:1973;449-450.
30. Palkovits M., Brownstein M.J. Maps and Guide to Microdissection of the Rat Brain. 1988;Elsevier, New York.
31. Pechnick R.N. Effects of opioids on the hypothalamo-pituitary-adrenal axis. Annu. Rev. Pharmacol. Toxicol. 32:1993;353-382.
32. Schulz S., Höllt V. Opioid withdrawal activities MAP kinase in locus coeruleus neurons in morphine-dependent rats in vivo. Eur. J. Neurosci. 10:1998;1196-1201.
33. Self D.W., Nestler E.J. Molecular mechanisms of drug reinforcement and addiction. Annu. Rev. Neurosci. 18:1995;463-495.
34. Taylor S.S., Knighton D.R., Zheng J., Ten Eyck L.F., Sowadski J.M. Structural framework for the protein kinase family. Annu. Rev. Cell Biol. 8:1992;429-462.
35. Tokuyama S., Feng Y., Wakabayashi H., Ho I.K. Possible involvement of protein kinases in physical dependence on opioids: studies using protein kinase inhibitors, H-7 and H-8. Eur. J. Pharmacol. 284:1995;101-107.
36. Tokuyama S., Ho I.K., Yamamoto T. A protein kinase inhibitor, H-7, blocks naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats. Brain Res. Bull. 52:2000;363-369.
37. Van Haasteren G., Li S., Muda M., Susini S., Schlegel W. Calcium signalling and gene expression. J. Recept. Signal Transduct. Res. 19:1999;481-492.
38. Vargas M.L., Martínez-Piñero M.G., Milanés M.V. Neurochemical activity of noradrenergic neurons and pituitary-adrenal response after naloxone-induced withdrawal: the role of calcium channels. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;501-506.
39. Vargas M.L., Abella C., Hernández J. Diazepam increases the hypothalamic-pituitary-adrenocortical (hypothalamus-pituitary-adrenocortical) axis activity by a cyclic AMP-dependent mechanism. Br. J. Pharmacol. 133:2001;1355-1361.
40. Whitnall M.H. Regulation of the hypothalamic corticotropin-releasing hormone neurosecretory system. Prog. Neurobiol. 40:1993;573-629.